Steve Buechler produced our first LLS Community member written content. We are excited to provide this opportunity to other members of our online network as well. Steve shares his own experience as a person diagnosed with AML in the article below.
We’ve come a long way and we continue to make substantial progress. The outlook for blood cancer patients is better than ever, but it’s still nowhere near good enough. With more than $233 million dollars currently committed to research into every type of blood cancer, you can be sure LLS
LLS and blood cancer advocates are celebrating after our efforts helped make two bills become law in California, advancing health equity and improving cancer care for thousands.
Today, cancer patients—and others with other chronic conditions—are breathing a collective sigh of relief. After years of relentless efforts by LLS staff and blood cancer advocates, President Biden just signed into law the Inflation Reduction Act and its key health provisions which will make healthcare more affordable for millions.
The Food and Drug Administration (FDA) approved azacitidine (Vidaza®) for pediatric patients 1 month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML). JMML is an aggressive and difficult to treat disease.